Arca Biopharma Stock Analysis

ABIO Stock  USD 1.72  0.03  1.78%   
ARCA Biopharma is fairly valued with Real Value of 1.67 and Hype Value of 1.68. The main objective of ARCA Biopharma stock analysis is to determine its intrinsic value, which is an estimate of what ARCA Biopharma is worth, separate from its market price. There are two main types of ARCA Biopharma's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect ARCA Biopharma's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of ARCA Biopharma's stock to identify patterns and trends that may indicate its future price movements.
The ARCA Biopharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. ARCA Biopharma is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. ARCA Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and ARCA Biopharma's ongoing operational relationships across important fundamental and technical indicators.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ARCA Biopharma. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.

ARCA Stock Analysis Notes

About 52.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.66. Some equities with similar Price to Book (P/B) outperform the market in the long run. ARCA Biopharma recorded a loss per share of 0.37. The entity last dividend was issued on the 4th of April 2019. The firm had 1:18 split on the 4th of April 2019. ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. The company was incorporated in 2004 and is headquartered in Westminster, Colorado. Arca Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people. For more info on ARCA Biopharma please contact Michael Bristow at 720 940 2200 or go to https://www.arcabio.com.

ARCA Biopharma Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. ARCA Biopharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding ARCA Biopharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
ARCA Biopharma may become a speculative penny stock
Net Loss for the year was (5.34 M) with profit before overhead, payroll, taxes, and interest of 0.
ARCA Biopharma currently holds about 46.44 M in cash with (5.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
ARCA Biopharma has a poor financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Acquisition by Daniel Mitchell of 6000 shares of ARCA Biopharma at 1.64 subject to Rule 16b-3

ARCA Biopharma Upcoming and Recent Events

Earnings reports are used by ARCA Biopharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ARCA Biopharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
23rd of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

ARCA Largest EPS Surprises

Earnings surprises can significantly impact ARCA Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-02-18
2019-12-31-0.99-0.770.2222 
2019-11-06
2019-09-30-1.3-0.760.5441 
2019-08-01
2019-06-30-1.86-1.140.7238 
View All Earnings Estimates

ARCA Biopharma Thematic Classifications

In addition to having ARCA Biopharma stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Biotech Idea
Biotech
Biotechnology and pharmaceuticals production and services

ARCA Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as ARCA Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ARCA Biopharma backward and forwards among themselves. ARCA Biopharma's institutional investor refers to the entity that pools money to purchase ARCA Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Northern Trust Corp2023-12-31
21 K
Charles Schwab Investment Management Inc2023-12-31
15 K
Two Sigma Securities, Llc2023-12-31
12.1 K
Tower Research Capital Llc2023-12-31
K
Ubs Group Ag2023-12-31
1.1 K
Parallel Advisors, Llc2023-12-31
244
Simplex Trading, Llc2023-12-31
100.0
Wells Fargo & Co2023-12-31
79.0
Royal Bank Of Canada2023-12-31
56.0
Cable Car Capital Llc2023-12-31
M
Western Standard Llc2023-12-31
1.4 M
Note, although ARCA Biopharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

ARCA Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 24.94 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ARCA Biopharma's market, we take the total number of its shares issued and multiply it by ARCA Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

ARCA Profitablity

ARCA Biopharma's profitability indicators refer to fundamental financial ratios that showcase ARCA Biopharma's ability to generate income relative to its revenue or operating costs. If, let's say, ARCA Biopharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, ARCA Biopharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of ARCA Biopharma's profitability requires more research than a typical breakdown of ARCA Biopharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2024
Return On Capital Employed(0.20)(0.21)
Return On Assets(0.14)(0.15)
Return On Equity(0.14)(0.15)

Management Efficiency

ARCA Biopharma has return on total asset (ROA) of (0.1102) % which means that it has lost $0.1102 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1357) %, meaning that it created substantial loss on money invested by shareholders. ARCA Biopharma's management efficiency ratios could be used to measure how well ARCA Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of March 2024, Return On Capital Employed is likely to drop to -0.21. In addition to that, Return On Assets is likely to drop to -0.15. As of the 19th of March 2024, Asset Turnover is likely to grow to 0.30, while Total Assets are likely to drop about 34.9 M.
Last ReportedProjected for 2024
Price Book Value Ratio 0.66  0.63 
Enterprise Value Multiple 1.73  1.82 
Price Fair Value 0.66  0.63 
The analysis of ARCA Biopharma's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze ARCA Biopharma's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of ARCA Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
1.146

Technical Drivers

As of the 19th of March, ARCA Biopharma owns the market risk adjusted performance of (0.07), and Variance of 2.36. ARCA Biopharma technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume patterns, or the prices will eventually revert. We were able to collect and analyze data for thirteen technical drivers for ARCA Biopharma, which can be compared to its peers in the sector. Please confirm ARCA Biopharma standard deviation, as well as the relationship between the maximum drawdown and kurtosis to decide if ARCA Biopharma is priced correctly, providing market reflects its prevailing price of 1.72 per share. Please also double-check ARCA Biopharma jensen alpha, which is currently at (0.18) to validate the company can sustain itself in the future.

ARCA Biopharma Price Movement Analysis

Execute Study
The output start index for this execution was nine with a total number of output elements of fifty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. ARCA Biopharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for ARCA Biopharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

ARCA Biopharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ARCA Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on ARCA Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ARCA Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

ARCA Biopharma Predictive Daily Indicators

ARCA Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ARCA Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

ARCA Biopharma Forecast Models

ARCA Biopharma's time-series forecasting models are one of many ARCA Biopharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ARCA Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About ARCA Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how ARCA Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ARCA shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ARCA Biopharma. By using and applying ARCA Stock analysis, traders can create a robust methodology for identifying ARCA entry and exit points for their positions.
Last ReportedProjected for 2024
Pretax Profit Margin(2.26)(2.37)
Operating Profit Margin(2.51)(2.63)
Net Loss(2.26)(2.37)
Gross Profit Margin 1.08  1.02 

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding ARCA Biopharma to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Cryptocurrency Center Now

   

Cryptocurrency Center

Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
All  Next Launch Module
When determining whether ARCA Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ARCA Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arca Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arca Biopharma Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ARCA Biopharma. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for ARCA Stock analysis

When running ARCA Biopharma's price analysis, check to measure ARCA Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARCA Biopharma is operating at the current time. Most of ARCA Biopharma's value examination focuses on studying past and present price action to predict the probability of ARCA Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARCA Biopharma's price. Additionally, you may evaluate how the addition of ARCA Biopharma to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Is ARCA Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ARCA Biopharma. If investors know ARCA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ARCA Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.37)
Return On Assets
(0.11)
Return On Equity
(0.14)
The market value of ARCA Biopharma is measured differently than its book value, which is the value of ARCA that is recorded on the company's balance sheet. Investors also form their own opinion of ARCA Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ARCA Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARCA Biopharma's market value can be influenced by many factors that don't directly affect ARCA Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARCA Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARCA Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARCA Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.